Transcend Capital Advisors LLC Has $1.66 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Transcend Capital Advisors LLC cut its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 22.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 69,195 shares of the company's stock after selling 19,687 shares during the period. Transcend Capital Advisors LLC's holdings in Kenvue were worth $1,659,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. SRS Capital Advisors Inc. raised its stake in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after buying an additional 571 shares in the last quarter. Clarity Asset Management Inc. bought a new stake in Kenvue in the fourth quarter valued at about $45,000. SBI Securities Co. Ltd. acquired a new position in Kenvue in the fourth quarter worth about $46,000. Continuum Advisory LLC boosted its holdings in Kenvue by 2,071.1% during the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,864 shares in the last quarter. Finally, Golden State Wealth Management LLC grew its stake in shares of Kenvue by 292.0% in the 1st quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company's stock valued at $74,000 after purchasing an additional 2,295 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price for the company. UBS Group raised their price target on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Evercore ISI began coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price for the company. Barclays increased their price target on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Monday, May 12th. Finally, Citigroup restated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Kenvue presently has an average rating of "Hold" and a consensus price target of $25.33.

Kenvue Stock Performance

Shares of Kenvue stock opened at $20.89 on Friday. The firm has a fifty day moving average of $22.85 and a two-hundred day moving average of $22.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. The stock has a market capitalization of $40.07 billion, a price-to-earnings ratio of 37.97, a PEG ratio of 3.28 and a beta of 0.98. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same quarter in the prior year, the company posted $0.28 earnings per share. The firm's revenue was down 3.9% on a year-over-year basis. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.93%. Kenvue's dividend payout ratio is 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.